English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim: To study the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (BAK)-free versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension. Settings and Design: Prospective, randomized, comparative study in 30 patients of POAG/ocular hypertension with moderate glaucomatous damage were included. Material and Methods: The patients were randomly assigned to one of the two treatment groups, each having a sample size of 15 patients. All the patients were subjected to the detailed ocular examination at baseline and 12 weeks after starting the study treatment. Results: No significant difference in mean intraocular pressure (IOP) was observed between latanoprost at baseline and travoprost BAK-free after 12 weeks nor were significant differences noted in mean ocular hyperemia, visual acuity, corneal fluorescein staining, or overall scores from the Ocular Surface Disease Index. Patients had a significantly shorter mean tear breakup time while on latanoprost compared with travoprost BAK-free. Conclusion: The results of this study showed that both the groups had similar IOP control with better anterior segment signs in patients treated with travoprost BAK-free monotherapy .

iosr journal of dental and medical sciences

To study the Efficacy and safety of travoprost 0.004% BAK-free versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension.